Show simple item record

dc.contributor.authorAydinli, Kilic
dc.contributor.authorKaleli, Semih
dc.contributor.authorGunel, Tuba
dc.contributor.authorBenian, Ali
dc.contributor.authorZeybek, Yosun Gorkem
dc.date.accessioned2021-03-04T09:32:08Z
dc.date.available2021-03-04T09:32:08Z
dc.date.issued2013
dc.identifier.citationZeybek Y. G. , Gunel T., Benian A., Aydinli K., Kaleli S., "Clinical evaluations of cell-free fetal DNA quantities in pre-eclamptic pregnancies", JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, cilt.39, sa.3, ss.632-640, 2013
dc.identifier.issn1341-8076
dc.identifier.othervv_1032021
dc.identifier.otherav_68af6aab-bcb2-44fc-b30c-8afa1b206b8a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/72541
dc.identifier.urihttps://doi.org/10.1111/j.1447-0756.2012.02011.x
dc.description.abstractAim Quantitative changes of cell-free fetal DNA in maternal plasma as an indicator for impending pre-eclampsia was reported in different studies. Cell-free fetal nucleic acids can be detected in maternal circulation during pregnancy. Our aim was to determine the higher rate of fetal DNA levels in maternal blood in pre-eclampsia compared to normal pregnancies and the clinical use of real-time polymerase chain reaction (PCR) in the Turkish population as a marker. Material and Methods According to their gestational ages, the plasma levels of 30 pre-eclamptic women at 2640 weeks of pregnancy were matched with 18 healthy pregnant women. Cell-free fetal DNA levels in maternal plasma were compared using real-time PCR technology. For the quantitative measurement of fetal DNA from maternal blood, the relative quantification PCR process was applied to all samples, using SRY and GAPDH genes. These patients were classified as pre-eclamptic and control groups and were matched according to weeks of pregnancy. Results Free fetal DNA levels of 30 pre-eclamptic patients were compared to healthy pregnant women and an average 3.06-fold increase was observed. During the second trimester, free fetal DNA levels were 1.5 times higher in pre-eclamptic patients. This increase was 3.5-fold during the third trimester. The DNA increase of pre-eclamptic patients was 4.1-fold and 3.4-fold during 29th33rd and 34th40th weeks, respectively. Conclusions Cell-free fetal DNA in maternal blood could be used as a marker for identifying subjects at increased risk of developing pre-eclampsia.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectKADIN HASTALIKLARI & DOĞUM
dc.subjectKlinik Tıp
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectCerrahi Tıp Bilimleri
dc.subjectKadın Hastalıkları ve Doğum
dc.subjectObstetrics and Gynecology
dc.subjectHealth Sciences
dc.titleClinical evaluations of cell-free fetal DNA quantities in pre-eclamptic pregnancies
dc.typeMakale
dc.relation.journalJOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume39
dc.identifier.issue3
dc.identifier.startpage632
dc.identifier.endpage640
dc.contributor.firstauthorID55862


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record